<H1>Chapter DOI: 10.1007/978-1-60327-829-4_24<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>52</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>51</td></tr><tr><td>BibStructured Count</td><td width="10%">50</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>48</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_24</td><td>BibArticle</td><td>Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423(6937):337&#8211;42.</td><td><a href=http://dx.doi.org/10.1038/nature01658>10.1038/nature01658</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_24</td><td>BibArticle</td><td>Clarke NW, McClure J, George NJ. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993;24(2):286&#8211;90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_24</td><td>BibArticle</td><td>Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88(12 Suppl):2919&#8211;26.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20000615)88:12+&lt;2919::AID-CNCR7&gt;3.0.CO;2-Z>10.1002/1097-0142(20000615)88:12+&lt;2919::AID-CNCR7&gt;3.0.CO;2-Z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_24</td><td>BibArticle</td><td>Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2006;12(11 Pt 1):3361&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-0269>10.1158/1078-0432.CCR-06-0269</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_24</td><td>BibArticle</td><td>Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059&#8211;66.</td><td><a href=http://dx.doi.org/10.1359/JBMR.040305>10.1359/JBMR.040305</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_24</td><td>BibArticle</td><td>Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161(4):1219&#8211;22.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)61639-2>10.1016/S0022-5347(01)61639-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_24</td><td>BibArticle</td><td>Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345(13):948&#8211;55.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa010845>10.1056/NEJMoa010845</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_24</td><td>BibArticle</td><td>Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray asbsorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167(6):2361&#8211;7; discussion 7.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64985-3>10.1016/S0022-5347(05)64985-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_24</td><td>BibArticle</td><td>Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163(1):181&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)68000-7>10.1016/S0022-5347(05)68000-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_24</td><td>BibArticle</td><td>Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83(8):1561&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0142(19981015)83:8&lt;1561::AID-CNCR11&gt;3.0.CO;2-Z>10.1002/(SICI)1097-0142(19981015)83:8&lt;1561::AID-CNCR11&gt;3.0.CO;2-Z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_24</td><td>BibArticle</td><td>Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008&#8211;12.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000063820.94994.95>10.1097/01.ju.0000063820.94994.95</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_24</td><td>BibArticle</td><td>Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352(2):154&#8211;64.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041943>10.1056/NEJMoa041943</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_24</td><td>BibArticle</td><td>Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23(31):7897&#8211;903.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.00.6908>10.1200/JCO.2004.00.6908</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_24</td><td>BibArticle</td><td>Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175(1):136&#8211;9; discussion 9.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)00033-9>10.1016/S0022-5347(05)00033-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_24</td><td>BibArticle</td><td>Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79(6):933&#8211;41.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.1997.00234.x>10.1046/j.1464-410X.1997.00234.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_24</td><td>BibArticle</td><td>Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14(10):1468&#8211;76.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdg401>10.1093/annonc/mdg401</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_24</td><td>BibArticle</td><td>Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96(1):133&#8211;8.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.1.133>10.1073/pnas.96.1.133</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_24</td><td>BibArticle</td><td>Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209&#8211;57.</td><td><a href=http://dx.doi.org/10.1196/annals.1402.089>10.1196/annals.1402.089</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_24</td><td>BibArticle</td><td>Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7(5):377&#8211;87.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_24</td><td>BibArticle</td><td>Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial&#8211;the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150&#8211;7.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.04.105>10.1200/JCO.2003.04.105</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_24</td><td>BibArticle</td><td>Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458&#8211;68.</td><td><a href=http://dx.doi.org/10.1093/jnci/94.19.1458>10.1093/jnci/94.19.1458</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_24</td><td>BibArticle</td><td>Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11):879&#8211;82.</td><td><a href=http://dx.doi.org/10.1093/jnci/djh141>10.1093/jnci/djh141</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_24</td><td>BibArticle</td><td>Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21(23):4277&#8211;84.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.05.147>10.1200/JCO.2003.05.147</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_24</td><td>BibArticle</td><td>Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21(17):3335&#8211;42.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.03.042>10.1200/JCO.2003.03.042</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_24</td><td>BibArticle</td><td>Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95(17):1300&#8211;11.</td><td><a href=http://dx.doi.org/10.1093/jnci/djg038>10.1093/jnci/djg038</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_24</td><td>BibArticle</td><td>Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007;99(10):765&#8211;76.</td><td><a href=http://dx.doi.org/10.1093/jnci/djk178>10.1093/jnci/djk178</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_24</td><td>BibArticle</td><td>Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918&#8211;25.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.01.529>10.1200/JCO.2005.01.529</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_24</td><td>BibArticle</td><td>Major PP, Cook RJ, Chen BL, Zheng M. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005;2(4):234&#8211;40.</td><td><a href=http://dx.doi.org/10.3816/SCT.2005.n.017>10.3816/SCT.2005.n.017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_24</td><td>BibArticle</td><td>Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21(5):389&#8211;406.</td><td><a href=http://dx.doi.org/10.2165/00002018-199921050-00004>10.2165/00002018-199921050-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_24</td><td>BibArticle</td><td>Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64(1):281&#8211;9.</td><td><a href=http://dx.doi.org/10.1046/j.1523-1755.2003.00071.x>10.1046/j.1523-1755.2003.00071.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_24</td><td>BibArticle</td><td>Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349(17):1676&#8211;9; discussion 9.</td><td><a href=http://dx.doi.org/10.1056/NEJM200310233491721>10.1056/NEJM200310233491721</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_24</td><td>BibUnstructured</td><td>Zometa. Full prescribing information. Novartis Pharmaceuti-cals Corporation. Rev: October <span style='background:#66FF66'>2009</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_24</td><td>BibArticle</td><td>Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0278-2391(03)00720-1>10.1016/S0278-2391(03)00720-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_24</td><td>BibArticle</td><td>Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527&#8211;34.</td><td><a href=http://dx.doi.org/10.1016/j.joms.2004.02.004>10.1016/j.joms.2004.02.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_24</td><td>BibArticle</td><td>Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369&#8211;76.</td><td><a href=http://dx.doi.org/10.1016/j.joms.2006.11.003>10.1016/j.joms.2006.11.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_24</td><td>BibArticle</td><td>Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65(7):1328&#8211;31.</td><td><a href=http://dx.doi.org/10.1016/j.joms.2007.03.006>10.1016/j.joms.2007.03.006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_24</td><td>BibArticle</td><td>Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23(6):826&#8211;36.</td><td><a href=http://dx.doi.org/10.1359/jbmr.080205>10.1359/jbmr.080205</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_24</td><td>BibArticle</td><td>Vescovi P, Manfredi M, Merigo E, Meleti M. Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2008;66(4):831&#8211;2.</td><td><a href=http://dx.doi.org/10.1016/j.joms.2007.11.025>10.1016/j.joms.2007.11.025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_24</td><td>BibArticle</td><td>Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12(4):1221&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-1933>10.1158/1078-0432.CCR-05-1933</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_24</td><td>BibArticle</td><td>Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358(14):1474&#8211;82.</td><td><a href=http://dx.doi.org/10.1056/NEJMcp0707217>10.1056/NEJMcp0707217</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_24</td><td>BibArticle</td><td>Seeman E. The structural basis of bone fragility in men. Bone 1999;25(1):143&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S8756-3282(99)00117-9>10.1016/S8756-3282(99)00117-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_24</td><td>BibArticle</td><td>Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab 1999;84(10):3431&#8211;4.</td><td><a href=http://dx.doi.org/10.1210/jc.84.10.3431>10.1210/jc.84.10.3431</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_24</td><td>BibArticle</td><td>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238&#8211;44.</td><td><a href=http://dx.doi.org/10.1001/jama.294.2.238>10.1001/jama.294.2.238</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_24</td><td>BibArticle</td><td>Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008;93(1):2&#8211;7.</td><td><a href=http://dx.doi.org/10.1210/jc.2007-1402>10.1210/jc.2007-1402</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_24</td><td>BibArticle</td><td>Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001;345(13):948&#8211;55.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa010845>10.1056/NEJMoa010845</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_24</td><td>BibArticle</td><td>Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001;92(6):1444&#8211;50.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20010915)92:6&lt;1444::AID-CNCR1468&gt;3.0.CO;2-M>10.1002/1097-0142(20010915)92:6&lt;1444::AID-CNCR1468&gt;3.0.CO;2-M</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_24</td><td>BibArticle</td><td>Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008&#8211;12.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000063820.94994.95>10.1097/01.ju.0000063820.94994.95</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_24</td><td>BibArticle</td><td>Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25(9):1038&#8211;42.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.07.3361>10.1200/JCO.2006.07.3361</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_24</td><td>BibArticle</td><td>Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146(6):416&#8211;24.</td><td><a href=http://dx.doi.org/10.7326/0003-4819-146-6-200703200-00006>10.7326/0003-4819-146-6-200703200-00006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_24</td><td>BibArticle</td><td>Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89(8):3841&#8211;6.</td><td><a href=http://dx.doi.org/10.1210/jc.2003-032058>10.1210/jc.2003-032058</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_24</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Steiner</span> <span style='background:#DDDDDD'>MS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Patterson</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Israeli</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Barnette</span> <span style='background:#DDDDDD'>KG</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Boger</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Price</span> <span style='background:#DDDDDD'>D.</span></span></aug> Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer. Proc ASCO (abstract <span style='background:#66FF66'>4597</span>) 2004.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR53_24</td><td>BibArticle</td><td>Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179(1):152&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.08.137>10.1016/j.juro.2007.08.137</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>